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Abstract
Purpose Breast cancers detected at screening need less aggressive treatment compared to breast cancers detected due to 
symptoms. The evidence on the quality of life associated with screen-detected versus symptomatic breast cancer is sparse. 
This study aimed to compare quality of life among Norwegian women with symptomatic, screen-detected and interval breast 
cancer, and women without breast cancer and investigate quality adjusted life years (QALYs) for women with breast cancer 
from the third to 14th year since diagnosis.
Methods This retrospective cross-sectional study was focused on women aged 50 and older. A self-reported questionnaire 
including EQ-5D-5L was sent to 11,500 women. Multivariable median regression was used to analyze the association 
between quality of life score (visual analogue scale 0–100) and detection mode. Health utility values representing women’s 
health status were extracted from EQ-5D-5L. QALYs were estimated by summing up the health utility values for women 
stratified by detection mode for each year between the third and the 14th year since breast cancer diagnosis, assuming that 
all women would survive.
Results Adjusted regression analyses showed that women with screen-detected (n = 1206), interval cancer (n = 1005) and 
those without breast cancer (n = 1255) reported a higher median quality of life score using women with symptomatic cancer 
(n = 1021) as reference; 3.7 (95%CI 2.2–5.2), 2.3 (95%CI 0.7–3.8) and 4.8 (95%CI 3.3–6.4), respectively. Women with 
symptomatic, screen-detected and interval cancer would experience 9.5, 9.6 and 9.5 QALYs, respectively, between the third 
and the 14th year since diagnosis.
Conclusion Women with screen-detected or interval breast cancer reported better quality of life compared to women with 
symptomatic cancer. The findings add benefits of organized mammographic screening.
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Plain English summary
1. Why is this study needed?
To our knowledge, this is the first study reporting qual-
ity of life outcomes by detection mode, or for women with 
symptomatic, screen-detected and interval cancer and 
women without breast cancer.
2. What is the key problem/issue/question this manuscript 
addresses?
The key questions are if the women without any diag-
nosis of breast cancer have higher quality of life compared 
to women with breast cancer regardless of detection mode, 
and if women with symptomatic cancer have lower qual-
ity of life compared to women with screen-detected or 
interval cancer.
3. What is the main point of your study?
The study aimed to investigate quality of life among 
women by detection mode, including symptomatic, screen-
detected, and interval cancer, and among women without 
breast cancer.
4. What are your main results and what do they mean?
Women with screen-detected and interval cancer had 
higher scores of self-reported quality of life compared 
to women with symptomatic breast cancer in this study. 
Women with screen-detected breast cancer had higher scores 
of health utility values obtained from EQ-5D-5L compared 
to women with symptomatic breast cancer. When compared 
to women without breast cancer, the quality of life scores 
for breast cancer survivors were lower. These results are 
valuable in the policy discussions about cost-effectiveness 
of mammographic screening and should be considered in 
favor of organized screening.
Introduction
Breast cancer is the most common cancer and the second 
leading cause of cancer death among women in Norway 
and worldwide [1, 2]. Reduced breast cancer mortality due 
to early detection and improved treatment has received 
substantial attention during the last decades [3, 4], while 
less attention has been given to side effects of the treat-
ment and quality of life [5].
The World Health Organization defines quality of life as 
an individual’s perception of their position in life related 
to the culture and value systems in which they live [6]. 
Health-related quality of life is defined as perceived physi-
cal and mental health over time [7]. The concept of quality 
of life is essential in the evaluation of the side- and long-
term effects of cancer treatment. Examples of such effects 
among breast cancer survivors include cardiac and pulmo-
nary toxicity, reproductive dysfunction, arm lymphedema, 
neuropathy, skin changes, chronic pain, fatigue, depression 
and anxiety [8, 9]. Quality-adjusted life years (QALYs) 
combine the length and the quality of life, and reflect the 
person’s ability to carry out the activities of daily living 
without pain and mental disturbance [10]. If the quality 
of life is measured on a scale where 0 represents ‘death’ 
and 1 ‘perfect health’, the number of QALYs experienced 
is estimated by multiplying the expected length of life by 
the expected quality of life [10].
Organized mammographic screening aims to reduce 
breast cancer mortality by detecting tumors at an early stage, 
and thereby reduce the burden of treatment. Results from 
international review studies and BreastScreen Norway, a 
population-based cancer screening program, have shown a 
reduction in breast cancer mortality of 20–30% due to imple-
mentation of organized screening [3, 11].
Symptomatic cancer is associated with less favorable 
prognostic and predictive histopathologic tumor charac-
teristics compared to screen-detected cancer [12]. Women 
with symptomatic cancer can thus receive more aggressive 
treatment and are expected to have lower quality of life than 
those with screen-detected cancer [13]. Although various 
interventions and quality of life for breast cancer survivors 
have been evaluated [5, 14], we are not aware of any studies 
reporting the quality of life or QALYs following treatment 
of women with symptomatic cancer versus screen-detected 
cancer.
Interval cancers, breast cancers diagnosed due to symp-
toms between two screening examinations where the for-
mer was negative, might have similar histopathologic tumor 
characteristics to symptomatic cancers [15]. Women with 
interval cancer may therefore be treated more aggressively 
than those with screen-detected cancer, and this might influ-
ence their quality of life.
The objective of this study was to compare quality of 
life among women by detection mode, including symp-
tomatic, screen-detected, and interval cancer, and among 
women without breast cancer. We also aimed to estimate 
QALYs among women diagnosed with breast cancer, by 
detection mode. We hypothesized that women without 
any diagnosis of breast cancer have higher quality of life 
compared to women treated for breast cancer regardless of 
detection mode, and that women with symptomatic cancer 
would report lower quality of life compared to women with 
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screen-detected cancer due to detection and treatment of the 
cancer in an earlier stage.
Materials and methods
Study design and participants
This retrospective cross-sectional study was based on infor-
mation from BreastScreen Norway, which offers all female 
residents aged 50–69 biennial mammographic screening 
[16]. The program became nationwide in 2005. The annual 
participation rate in the program is 76% and 84% of the 
women had attended at least once during the first 20 years 
of the program [16]. In 2019, 3726 Norwegian women were 
diagnosed and treated for invasive breast cancer in Norway, 
including about 1500 screen-detected or interval cancers [2].
A paper-based self-administered questionnaire, developed 
in collaboration with breast cancer survivors and women 
without breast cancer, was used to collect data on quality of 
life and calculate QALYs among women with breast cancer 
from the third to the 14th year since diagnosis and among 
women without breast cancer. The Cancer Registry contains 
screening data since the start-up of the program in 1996 and 
provided data of the included women for at least 14 years 
back in time.
The questionnaire included a page with an informed 
consent regarding privacy and participation in the study. 
The questionnaire was sent to the women per post between 
December 11, 2019 and March 14, 2020: women with symp-
tomatic cancer between January 12 and 28, 2020; women 
with screen-detected cancer between December 18, 2019 
and January 10, 2020; women with interval cancer between 
January 24 and February 20, 2020, and women without 
breast cancer between February 10 and March 4, 2020. 
The women were asked to respond to the questionnaire and 
return it in a prepaid envelope within two weeks. A pilot, 
including 25 women, was performed four months prior 
the study start. The overall response rate for the pilot was 
44%; 3/6 (50%) women with symptomatic cancer, 4/7 (57%) 
screen-detected cancer; 3/6 (50%) interval cancer, and 1/6 
(17%) women without breast cancer. These response rates 
were used to estimate the sample size. Power-estimations 
indicated a need for a minimum of 1000 women in each of 
the four groups to show a 0.25-point difference in QALY 
between the groups with 80% power.
A total of 2500 women with symptomatic cancer, 2500 
with screen-detected cancer, 2500 with interval cancer and 
4000 women without breast cancer were randomly selected 
from the BreastScreen Norway database. Women aged 50–69 
at invitation to screening or at histologically verified inva-
sive breast cancer diagnosis (symptomatic, screen-detected 
or interval cancer), diagnosed 2006–2017 were eligible for 
inclusion. Symptomatic cancer was breast cancer diagnosed 
among women invited to the screening program, but either 
never attended or last attended more than two years prior to 
their diagnosis. Screen-detected cancer was breast cancer 
diagnosed as a result of a positive screening examination. 
Interval cancer was breast cancer diagnosed 0–24 months 
after a negative screening examination or 6–24 months after 
a false positive screening result [16]. Women without breast 
cancer had no registered invasive breast cancer or ductal car-
cinoma in situ in the breast in the Cancer Registry database 
before 2018.
Reporting all cancer types to the Cancer Registry of Nor-
way is mandatory for medical doctors, pathology laborato-
ries and hospitals [17]. Based on data from the Cancer Reg-
istry of Norway, we sent the questionnaire solely to women 
with primary breast cancer. Women without breast cancer 
were not registered with any cancer type. However, there is 
a delay in the reporting of cancer cases, which might have 
resulted in a cancer diagnosis between the date of extrac-
tion of the study population and the date when the women 
received the questionnaire. Women with primary breast 
cancer might have had other types of cancer diagnosed 
later in lifetime. Women in all the groups might also have 
experienced serious health conditions and symptoms sig-
nificantly decreasing their quality of life, but unrelated to 
breast cancer. Several symptoms and comorbidities, such as 
general pain, lymphedema, fatigue, joint pain, heart disease, 
breathing problems, etc., were included in the questionnaire, 
and the women, regardless of the study group, were asked 
to tick the box indicating these symptoms and conditions. 
The questionnaire also included open fields where women 
from all the groups were asked to fill in present condi-
tions and comorbidities. The latter information was used 
to exclude women with other cancer types or serious health 
conditions influencing quality of life (Fig. 1b). The question-
naire included questions about the treatment and relapse. 
As women with relapse were included in the study, it is 
assumed that some of them were in active treatment when 
they responded to the questionnaire.
The study was approved by the Regional Committees 
for Medical and Health Research Ethics (N28484) and reg-
istered at Clinical.Trials.gov (NCT03877029). A running 
number for each questionnaire was used to merge the self-
reported information with the database. The data were de-
identified prior to analyses. Research data used in the analy-
ses will be available by request, according to the General 
Data Protection Regulation [18].
Variables and data measurement
The questionnaire collected information about height (cm), 
weight (kg), education (no/primary school; secondary 
school; university/collage), physical activity (no/ < 2 h a 
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week; 2–3 h a week; > 3 h a week), appearance and body 
functioning (very satisfied; medium satisfied; little satisfied; 
not satisfied at all), breast cancer treatment [surgery (breast 
conserving/ mastectomy), chemotherapy, radiation therapy, 
and hormonal therapy], relapse (yes/no/do not know), and 
symptoms (general pain; fatigue; lymphedema). The self-
reported data on height and weight were used to calculate 
body mass index (BMI, kg/m2). Women without breast can-
cer received the questionnaire without questions on breast 
cancer diagnosis.
Information about age, detection mode, date of diagnosis, 
tumor diameter (mm), lymph node status (positive or nega-
tive), stage (I–IV, based on TNM classification) [19], and 
treatment was extracted from the Cancer Registry database. 
Self-reported information on treatment was  used if it was 
not available from the Cancer Registry database. In case of 
differences between the sources, the information from the 
database was used.
EQ-5D-5L questionnaire consisted of five dimensions 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) with five levels of severity (1–5), and a 
visual analogue scale (VAS) to report present health status 
(0–100) [20]. The response on VAS was included as the 
outcome in our analyses as a value of self-reported qual-
ity of life. The response to the questions regarding the five 
dimensions was used to obtain health utility values, repre-
senting the expected quality of life values on the day women 
responded to the questionnaire, which was approximated to 
one year period for the purposes of this study [20, 21]. We 
used ordinal regression to impute the missing numbers on 
the levels of severity, and available and imputed health util-
ity values were compared (Online Appendix, Table A1). 
Women’s EQ-5D-5L responses were transformed to EQ-
5D-3L responses using a cross-walk algorithm [21, 22], and 
health utility values were produced using the Danish value 
set for the EQ-5D-3L. We opted to use the Danish weights 
for the EQ-5D-3L to obtain the health utility values due to 
the absence of any Norwegian weights for the EQ-5D and 
because health and quality of life perceptions are compara-
ble for Norway and Denmark [23].
Statistical methods
Descriptive information was presented by detection mode 
and included means with standard deviations (SD) for con-
tinuous variables, median scores with interquartile ranges 
(IQR) for quality of life, and numbers with proportions for 
categorical variables. We used t-tests or analysis of vari-
ance (ANOVA) with the Bonferroni adjustment for mul-
tiple comparisons (level of significance post hoc < 0.001), 
nonparametric equality of medians test, and a chi-square 
test for comparisons. Sensitivity analyses were performed 
to compare the characteristics of the women who were and 
were not included in the analyses. To assess how quality 
of life was related to detection mode, two sets of regres-
sion analysis were performed. First, the association of the 
self-reported quality of life score (VAS, 0–100) and detec-
tion mode (women with symptomatic, screen-detected and 
interval cancer and women without breast cancer) was ana-
lysed using a median regression model adjusted for age, 
BMI, education, physical activity, appearance and body 
functioning, general pain, fatigue and lymphedema. A 
separate model for women with breast cancer also included 
time since diagnosis, stage at diagnosis, relapse and types 
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of treatment as adjusting variables. The fulfilled assump-
tions of normal regression, linearity and independence of 
observations, as well as the large sample size, were the 
main reasons to choose median regression. Missing val-
ues of BMI (n = 164) were imputed for regression analyses 
using a linear regression model. Missing values for each 
categorical variable were indicated as a dummy variable 
and were included in all regression models. Second, health 
utility values were used as an outcome variable in the lin-
ear regression models, adjusted for all available variables, 
separately for all four groups of women and for women 
with breast cancer. Unadjusted and adjusted health utility 
values with standard errors (SE) were used to graphically 
present trends from the third to the 14th year since breast 
cancer diagnosis for women with breast cancer and trends 
by age for all groups. The adjusted health utility values were 
obtained using a margin function for time since diagnosis 
or age after performing a fully adjusted regression model. 
As the data were obtained from each woman only once, we 
have assumed that every woman’s health status in each year 
following can be approximated by the sample mean for a 
succession of different groups of women by detection mode. 
When calculating QALYs, we did not adjust for overall or 
breast cancer specific survival, but assumed that all women 
survived for at least 14 years following diagnosis and for at 
least 67–83 years, depending on the age of diagnosis. The 
QALYs from the third to the 14th year since breast cancer 
diagnosis were calculated based on the health utility values 
from women per year since diagnosis stratified by detection 
mode. Numbers of women per year since diagnosis or age 
were also presented (Online Appendix, Table A2). Stata MP 
Version 16.1 (Stata, Texas, College Station) was used for 
analyses, while MS Excel was used to graphically present 
the health utility values over time. P values < 0.05 were con-
sidered statistically significant.
Results
We sent the questionnaire to 11,500 women (Fig. 1a, b). The 
response was not received from 6368 women, while 343 
explicitly refused to participate, and six women died before 
receiving the questionnaire. We excluded 276 women with 
no information on quality of life and 20 women due to self-
reported detrimental health conditions unrelated to breast 
cancer. The final study sample consisted of data from 4487 
(39%, 4487/11,500; of the sample at recruitment) women; 
1021 for symptomatic cancer, 1206 for screen-detected can-
cer, 1005 for interval cancer and 1255 for women without 
breast cancer.
Women included in the analyses, regardless of detection 
mode, were on average one year younger at recruitment and 
at diagnosis compared to those not included (p < 0.05 for all) 
(Table 1). Sensitivity analyses showed mean tumor diameter 
to be smaller and the proportion of lymph node positive 
tumors lower for women with symptomatic cancer included 
in the analyses, compared to those not included (20.3, SD: 
13.1 mm versus 22.2, 16.2 mm; 27.0%, 276/1021 versus 
30.8%, 455/1479, p < 0.05 for both). Results of sensitivity 
analyses of the tumours and the women included and not 
included in the analyses are shown in the Online Appendix 
(Table A3).
Among the included women, the proportion of women 
with university/college education was higher for women 
with symptomatic compared to screen-detected cancer 
(47.7%, 487/1021 versus 40.9%, 493/1206; p < 0.05) 
(Table 1). The proportion of women who underwent breast 
conserving surgery was higher for women with screen-
detected compared to symptomatic and interval cancer 
(71.4%, 861/1206 versus 51.3%, 524/1021 and 55.8%, 
561/1005; p < 0.05), while the proportion of women who 
underwent chemotherapy, as well as hormonal therapy, 
was lower for those with screen-detected compared to 
symptomatic and interval cancer (41.0%, 495/1206; 43.4%, 
523/1021 versus 53.9%, 550/1206; 48.1%, 491/1021 and 
57.0%, 573/1005; 51.0%, 513/1005, respectively) (p < 0.05 
for all).
Mean health utility value  was 0.77 (SD 0.16) for 
women with symptomatic cancer,  0.81 (SD: 0.14)  for 
women with screen-detected cancer, and 0.80 (SD: 0.13) 
for those with interval cancer (p < 0.05) (Table 1). Mean 
health utility value  was higher for women without breast 
cancer (0.83, SD: 0.13) compared to women with screen-
detected, symptomatic and interval cancer (p < 0.05 for 
all). Median values for quality of life were 60 (IQR: 
49–80) for women with symptomatic breast cancer, 70 
(IQR: 50-80) for those with screen-detected and interval 
cancer, and 80 (IQR: 70-90) for women without breast 
cancer.
In the adjusted regression analyses, women with screen-
detected and interval cancer, and women without breast 
cancer had a 3.7 (95%CI 2.2–5.2), 2.3 (95%CI 0.7–3.8), 
and 4.8 (95%CI 3.3–6.4) higher median quality of life 
score, respectively, using symptomatic cancer as reference 
(Table 2). Factors associated with a higher median qual-
ity of life score included secondary school or university/
college versus no/primary school and ≥ 2 hours a week 
versus < 2 hours a week of physical activity. Factors asso-
ciated with a lower median quality of life score included 
non-satisfaction with appearance and body functioning, 
aging, general pain, fatigue and lymphedema.
Health utility values of women with symptomatic, 
screen-detected and interval cancer tended to increase 
by time since diagnosis (Fig. 2). The lowest values were 
observed for the third year since diagnosis among women 
with symptomatic cancer (0.72, SE: 0.14) and the fifth 
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Table 1  Baseline characteristics of women included and not included in the analyses

























Age at recruitment 
Mean (SD), years
65.2 (6.8) 67.4 (6.3)* 67.4 (6.0)# 65.5 (7.4)§& 66.3 (7.0)~ 68.3 (6.5)*~ 68.1 (6.3)#~ 66.6(8.2)§&~
Age at diagnosis 
Mean (SD), years
57.3 (6.2) 59.9 (5.7)* 59.6 (5.4)# 58.5 (6.2)~ 60.4 (5.7)*~ 60.0 (5.4)#~
Time since diagnosis 
Mean (SD), years
8.0 (3.4) 7.6 (3.4)* 7.8 (3.5) 7.8 (3.3) 8.0 (3.4)~ 8.1 (3.4)#¤~
Tumor diameter
 Mean (SD), mm 20.3 (13.0) 17.2 (14.3)* 21.0 (13.5)¤ 22.2 (16.2)~ 16.9 (13.2)* 21.1 (13.7)¤
 Missing, n 264 30 72 389 36 102
 Positive lymph 
nodes, n (%)
276 (27.0) 349 (28.9) 258 (35.6)#¤ 455 (30.8)~ 373 (28.8) 522 (34.9)#
 Missing, n 382 18 31 555 29 44
Stage at diagnosis
 I, n (%) 393 (38.5) 697 (57.8)* 375 (37.3)¤ 487 (32.9)~ 743 (57.4)* 569 (38.9)#¤
 II, n (%) 397 (38.9) 283 (23.5)* 443 (44.1)#¤ 562 (38.0) 287 (22.2)* 615 (41.1)¤
 III, n (%) 149 (14.6) 194 (16.1) 132 (13.1) 272 (18.4)~ 208 (16.1) 211 (14.1)#
 IV, n (%) 28 (2.7) 8 (0.7) 8 (0.8) 60 (4.1) 17 (1.3) 20 (1.3)
 Missing, n 54 24 47 98 39 80
 Body mass index, 
kg/m2, mean (SD)
25.7 (4.4) 26.4 (4.3)* 25.4 (4.2)¤ 26.0 (4.4)&§
 Missing, n 29 41 29 65
Education
 No or primary 
school, n (%)
150 (14.7) 231 (19.2)* 185 (18.4) 223 (17.8)
 Secondary school, 
n (%)
376 (36.8) 469 (38.9) 350 (34.8) 488 (38.9)
 University/college, 
n (%)
487 (47.7) 493 (40.9)* 467 (46.5) 538 (42.9)
 Missing, n 8 13 3 6
Physical activity
 No or < 2 h a week, 
n (%)
189 (18.5) 218 (18.1) 131 (13.0) 166 (13.2)
 2–3 h a week, n (%) 389 (38.1) 524 (43.5) 429 (42.7) 509 (40.6)
 > 3 h a week, n (%) 433 (42.4) 449 (37.2) 440 (43.8) 569 (45.3)
 Missing, n 10 15 5 11
Appearance and 
body functioning
 Very satisfied, n 
(%)
151 (14.8) 203 (16.8) 167 (16.6) 235 (18.7)
 Medium satisfied, 
n (%)
460 (45.1) 586 (48.6) 505 (50.3) 671 (53.5)
 Little satisfied, n 
(%)
224 (21.9) 257 (21.3) 205 (20.4) 197 (15.7)
 Not satisfied at all, 
n (%)
170 (16.7) 135 (11.2) 116 (11.5) 71 (5.7)^&§
 Missing, n 16 25 12 81
 Surgery 1004 (98.3) 1201 (99.6) 994 (98.9)
 Breast conserving, 
n (%)
524 (51.3) 861 (71.4)* 561 (55.8)#¤
 Mastectomy, n (%) 480 (47.0) 340 (28.2)* 433 (43.1)¤
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SD standard deviation, IQR interquartile range
*p < 0.05 for women with symptomatic cancer versus screen-detected cancer
# p < 0.05 for women with symptomatic cancer versus interval cancer
¤p < 0.05 for women with screen-detected cancer versus interval cancer
^p < 0.05 for women with symptomatic cancer versus women without breast cancer
& p < 0.05 for women with screen-detected cancer versus women without breast cancer
§ p < 0.05 for women with interval cancer versus women without breast cancer
 ~p < 0.05 for corresponding included versus not included in the analyses
A two-sample t-test was used to compare means of continuous variables; a chi-square test was used to compare proportions of categorical variables
P < 0.001 between the groups for age recruitment and diagnosis, time since diagnosis, tumor diameter, body mass index and index values for 
one-way analysis of variance with Bonferroni adjustment for multiple comparisons
P < 0.05 between the groups for quality of life for nonparametric equality of medians test
Table 1  (continued)

























Missing, n - 3 1
 Chemotherapy, n 
(%)
550 (53.9) 495 (41.0)* 573 (57.0)¤
 Radiation therapy, 
n (%)
815 (79.8) 1039 (86.2)* 829 (82.5)
 Hormonal therapy, 
n (%)
491 (48.1) 523 (43.4)* 513 (51.0)¤
 Relapse, n (%) 105 (10.3) 77 (6.4) 38 (3.8) -
 General pain, n (%) 330 (32.3) 295 (24.5)* 282 (28.1) 300 (23.9)^
 Fatigue, n (%) 435 (42.6) 287 (32.1)* 345 (34.3) 111 (8.8)^&§
 Lymphedema, n 
(%)
163 (16.0) 154 (12.8) 141 (14.0) 14 (1.1)^&§
 Mobility, Mean 
(SD)
1.5 (0.8) 1.5 (0.8) 1.4 (0.8)¤ 1.3 (0.7)
 Self-care, Mean 
(SD)
1.1 (0.4) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3)
 Usual activities, 
Mean (SD)
1.7 (1.0) 1.5 (0.8) 1.6 (0.8)# 1.3 (0.6)^&§
 Pain/discomfort, 
Mean (SD)
2.2 (1.0) 2.0 (0.8) 2.1 (0.8) 2.0 (0.8)^
 Anxiety/depression 
Mean (SD)
1.7 (0.8) 1.5 (0.8) 1.5 (0.7) 1.4 (0.6)^
 Health utility value 
(0–1) Mean (SD)
0.77 (0.16) 0.81 (0.14)* 0.80 (0.13)# 0.83 
(0.13)^&§
Quality of life 
(0–100)
 Median (IQR) 60 (49–80) 70 (50–80) 70 (50–80) 80 (70–90)
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year since diagnosis among women with screen-detected 
cancer (0.76, SE: 0.09) and interval cancer (0.77, SE: 
0.05). The highest values were observed for the 11th year 
since diagnosis among women with screen-detected and 
interval cancer (0.84, SE: 0.09 and 0.83, SE: 0.07, respec-
tively) and 12th year since diagnosis among women with 
symptomatic cancer (0.83, SE: 0.05).
Based on Table A4b and Fig. A1a, we estimated that a 
woman aged 50–69 years when her symptomatic cancer 
was diagnosed, and survived for at least 14 years since 
diagnosis would experience 9.5 QALYs as compared to a 
similarly aged woman with screen-detected and interval 
cancer surviving for the same time would experience 9.6 
and 9.5 QALYs, respectively, during the period between 
the third and 14th year post-diagnosis.
The adjusted health utility values for all four groups did 
not show any specific trend by age, but generally tended 
to decrease from 0.81 (SE: 0.02)–0.82 (SE: 0.02) to 0.74 
(SE: 0.02)–0.75 (SE: 0.02) between 58 and 82 years (Figure 
A1b).
Table 2  The associations of the median self-reported quality of life 
score (EQ-5D-5L, visual analogue scale, 0–100) and different fac-
tors among women with symptomatic breast cancer, women with 
screen-detected breast cancer, women with interval breast cancer, and 
women without breast cancer, 2006–2017
*Adjusted for age, body mass index, education, physical activity, appearance and body functioning, general pain, fatigue and lymphedema
Unadjusted (n = 4487) Adjusted* (n = 4487)
Coefficient 95% Confidence Interval p value Coefficient 95% Confidence Interval p value
Mode of detection
 Symptomatic cancer Reference Reference
 Screen-detected cancer 10.0 8.3 to 11.7  < 0.01 3.7 2.2 to 5.2  < 0.01
 Interval cancer 10.0 8.2 to 11.8  < 0.01 2.3 0.7 to 3.8  < 0.01
 Women without breast cancer 20.0 18.3 to 21.7  < 0.01 4.8 3.3 to 6.4  < 0.01
Age (years) 0.00 − 0.05 to 0.05 1.00 − 0.22 − 0.3 to − 0.1  < 0.01
Body mass index (kg/m2) − 1.0 − 1.2 to − 0.9  < 0.01 − 0.1 − 0.3 to 0.1 0.22
Education
 No or primary school Reference Reference
 Secondary school 0.0 − 1.4 to 1.5 1.0 2.2 0.7 to 3.7  < 0.01
 University/college 1.0 − 0.4 to 2.4 0.17 4.6 3.1 to 6.1  < 0.01
 Missing 0.0 − 6.3 to 6.3 1.0 − 3.3 − 11.2 to 4.5 0.41
Physical activity
 No or < 2 h a week Reference Reference
 2–3 h a week 10.0 7.9 to 12.1  < 0.01 4.4 2.9 to 6.0  < 0.01
 > 3 h a week 15.0 12.9 to 17.1  < 0.01 6.1 4.5 to 7.8  < 0.01
 Missing 10.0 2.3 to 17.7 0.01 − 0.6 − 7.3 to 6.3 0.88
Appearance and body functioning
 Very satisfied Reference Reference
 Medium satisfied − 15.0 − 17.3 to − 12.7  < 0.01 − 9.4 − 10.8 to − 7.9  < 0.01
 Little satisfied − 25.0 − 27.7 to − 22.3  < 0.01 − 15.6 − 17.4 to − 13.8  < 0.01
 Not satisfied at all − 45.0 − 48.2 to − 41.9  < 0.01 − 25.9 − 28.2 to − 23.7  < 0.01
 Missing − 10.0 − 15.1 to − 4.9  < 0.01 − 8.3 − 11.7 to − 4.8  < 0.01
General pain
 No Reference Reference
 Yes − 18.0 − 20.8 to − 15.2  < 0.01 − 8.4 − 9.6 to − 7.1  < 0.01
Fatigue
 No Reference Reference
 Yes − 30.0 − 31.0 to − 29.0  < 0.01 − 15.6 − 16.9 to − 14.3  < 0.01
Lymphedema
 No Reference Reference
 Yes − 11.0 − 13.2 to − 8.8  < 0.01 − 3.9 − 5.7 to − 2.2  < 0.01
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Discussion
Women with screen-detected cancer,  interval cancer and 
those without breast cancer had a 3.7, 2.3, and 4.8 higher 
median quality of life score, respectively, compared to 
women with symptomatic cancer. Based on the data from 
our study, women  with symptomatic, screen-detected and 
interval cancer would experience 9.5, 9.6 and 9.5 QALYs, 
respectively, between the third and the 14th year since 
diagnosis.
As far as we are aware, no studies have compared and 
published breast cancer survivors’ quality of life by detection 
mode. The studies comparing quality of life of breast cancer 
survivors of screening age and women without breast can-
cer showed inconsistent results [24–26]. QALYs for women 
with breast cancer associated with screening have never been 
compared based on data reported by the women, but rather 
from opinions of health care professionals or epidemiolo-
gists [27, 28]. An ideal study design would include a pro-
spective study comparing quality of life and QALYs among 
women in the four groups over decades.
Breast cancer survivors who attended screening (screen-
detected and interval cancer) had higher scores of quality 
of life compared to women with symptomatic cancer. This 
might imply that women attending screening are healthier 
and/or have a higher health consciousness and possibly 
more informed about benefits and harms of mammographic 
screening. However, women with symptomatic cancer con-
sulted their general practitioner due to symptoms and might 
therefore also be better prepared for a cancer diagnosis as 
women with screen-detected cancer. Our finding of better 
quality of life among women with screen-detected com-
pared to symptomatic cancer might indicate that women 
with screen-detected cancer were treated less aggressively 
compared to women with symptomatic cancer. Furthermore, 
women with symptomatic cancer who were included in our 
study had more favorable histopathologic tumor characteris-
tics compared to those who were not included, which might 
have led to an overestimation of quality of life, and under-
estimation of the difference between women with sympto-
matic and screen-detected cancer. For women with screen-
detected cancer, no differences in tumor characteristics were 
observed for  those who were included and not included in 
the study. Women with interval cancer showed higher qual-
ity of life scores compared to women with symptomatic can-
cer. This finding might suggest that women with interval 
cancer are more aware of the first symptoms of the disease 
due to information attained at screening. When compared to 
women without breast cancer, the quality of life scores for 
breast cancer survivors were lower, indicating the impact 
of the disease on the quality of life perception. It should be 
noted that our hypotheses, regarding higher quality of life 
of women without breast cancer compared to women with 
breast cancer and lower quality of life of women with symp-
tomatic cancer compared to women with screen-detected and 
interval cancer, were confirmed.
The results on quality of life scores differed from  the 
results on mean health utility values in the adjusted analyses, 
where the value was higher solely for women with screen-
detected versus symptomatic cancer. Furthermore, trends 
over time showed consistently lower values for women 
with symptomatic cancer and women without breast can-
cer compared to screen-detected and interval cancer. This 
might indicate that women attending screening and diag-
nosed with breast cancer better manage the activities of daily 
living compared to women with symptomatic cancer and 
women without breast cancer. Possible reasons for this are 
not investigated in this study. We assume that the differ-
ences in VAS health status and QALYs across the groups 
are clinically meaningful as VAS indicates the participants’ 
perception of their general health condition while QALYs 
represent how the participants overcome daily living and 
are able to function. QALYs might thus be more clinically 
meaningful with regard to functioning compared to VAS. 
As far as we are aware, results of VAS and QALYs strati-
fied by detection mode has not been presented elsewhere. 
Fig. 2  Health utility values from EQ-5D-5L for women with symptomatic, screen-detected and interval cancer over the time period from the 
third to the 14th year since diagnosis. Whiskers are standard errors
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The results of the study are thus important in the effort of 
balancing the benefits and harms of mammographic screen-
ing and the policy discussions about the cost-effectiveness 
of organized screening. We considered the results to be in 
favor of organized mammographic screening.
The proportion of women with university/college edu-
cation was higher for women with symptomatic cancer 
compared to screen-detected cancer implying that women 
with higher education less frequently attend screening in 
Norway, which was also shown in a previous study using 
data from BreastScreen Norway [29]. Breast conserving 
surgery was more common, while chemotherapy and hor-
monal therapy were less common for women with screen-
detected cancer compared to women with symptomatic and 
interval cancer in our study. This suggests that women with 
screen-detected cancer had an advantage in received treat-
ment which might positively influenced their quality of life, 
compared to women with symptomatic and interval cancer. 
However, factors associated with changes in median quality 
of life included higher versus lower education and physi-
cal activity levels, non-satisfaction with appearance and 
body functioning, relapse, aging, general pain, fatigue and 
lymphedema. Breast cancer treatment was not associated 
with changes in quality of life or health utility values in our 
study. This might indicate that age, relapse and side-effects 
are more important determinants of quality of life in the 
long run than the treatment per se. Studies, not stratifying 
by detection mode, have shown that all these factors could 
affect quality of life among survivors [30–32].
Study limitations
We did not use a breast cancer specific questionnaire, as the 
study did not intend to investigate disease specific domains 
of quality of life since we also included women without 
breast cancer. Possible confounding factors, such as race, 
ethnicity, histologic grade, receptor status, breast cancer sub-
types and socio-economic status were not included as the 
data from the responding women and those available from 
the Cancer Registry of Norway was not complete and would 
have significantly reduced the sample size for the study if 
they had been included. These factors should be considered 
in future research. The response rates of women with inter-
val cancer and women without breast cancer were lower than 
anticipated and were possibly affected by the restrictions 
associated with COVID-19 pandemic, which started March 
13, 2020 in Norway. The response rate for women with 
screen-detected cancer was higher than for other groups. The 
reasons for this might be related to their confidence in mam-
mographic screening and generally better compliance with 
the requests from the health care provider and the interest in 
assessing and reporting the results of the service and health 
condition in connection with the service.
The Cancer Registry of Norway receives informa-
tion from the Population Registry regarding status, which 
includes date of death, immigration and emigration, every 
month. Some questionnaires were sent to women who had 
recently died and were not registered as dead in the Popula-
tion Registry. Therefore, we used reported information from 
the next-of-kin of the women if they were dead within the 
time slot from extracting the study population to the time 
of receiving the questionnaire in the postbox. Further, an 
overestimation of quality of life might have occurred due to 
the age difference between the women who were included 
and not included in the study. However, as the women in all 
the groups were younger, the small differences did not influ-
ence the results. Women unable to read and write in Nor-
wegian might have chosen not to participate, resulting in 
underestimation or overestimation of the effect, depending 
on numbers. A total of 217 women with screen-detected 
cancer were not included due to missing information about 
quality of life. The analyses of the baseline characteristics 
of women included versus not included due to missing 
information showed no significant differences (Table A5). 
Despite the relatively small differences in median quality 
of life between the groups, they might be clinically rele-
vant, as they reflected the consistently higher mean health 
utility values for women with screen-detected or interval 
cancer compared to women with symptomatic cancer over 
time. Using a dummy variable for the missing values of the 
categorical variables might be associated with the biased 
impact estimates and potentially lead to misspecification of 
the functional form of the analysis model [33]. However, 
as the study was based on complete data of the existing 
factors, inclusion of all covariates in a correctly speci-
fied impact model could help increase the precision of the 
impact estimates. The cross-walk algorithm used to obtain 
health utility values might be related to restrictions on the 
range of scale possible for 5L values when mapping to a 3L 
value set, which would result in lower values for a five-level 
system compared to a three-level system [21, 22]. Another 
limitation of the cross-walk was associated with the data 
from a different country, which would result in both higher 
and lower values depending on health perceptions [22]. We 
did not include information on survival when calculating 
QALYs, as all women in our study population were alive at 
data collection, and the average life expectancy for Norwe-
gian women, as of December 2017, is 84.3 years [34]. The 
latter was also the reason for non-adjusting for lead-time for 
women with screen-detected cancer [3].
Information bias was inevitable as the outcome was 
subjective and the assessment of the quality of life might 
have mostly been based on the presence or absence of 
breast cancer diagnosis. However, as the time since diag-
nosis was three to 14 years, the assessment of overall 
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health and quality of life was also relevant for the partici-
pating women.
The ideal study design would have been a prospective 
study following up the women during a long term. We 
were not able to follow the women during 10 years to pro-
vide the information on their quality of life over time in 
this study, due to limited funding.
In conclusion, our study found that women with breast 
cancers detected by screening might have better quality 
of life compared to women with breast cancers detected 
due to symptoms.
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